Biotech firm Gate2Brain, focused on developing therapeutics that efficiently cross biological barriers like the blood-brain barrier, has secured an $8.1M grant. The funding, provided by Shilpa Biocare Pvt Ltd, will advance the company's radically innovative peptide-based patented technology platform.
Gate2Brain's flagship product, G2B-002, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare paediatric cancers, serving as a proof of concept for its technology.













.png&w=3840&q=75)

